Association of A1AT With Poor Functional Outcome in Patients With Acute Ischemic Stroke [PDF]
Journal of the American Heart Association: Cardiovascular and Cerebrovascular DiseaseBackground This study aimed to investigate whether A1AT (α‐1 antitrypsin) bloodstream levels, measured acutely after ischemic stroke, can predict the outcome of patients with stroke.
Paula García‐Rodríguez +9 more
doaj +8 more sources
A1AT dysregulation of metabolically stressed hepatocytes by Kupffer cells drives MASH and fibrosis [PDF]
Experimental and Molecular MedicineMetabolic dysfunction-associated steatohepatitis (MASH) is associated with the activation of Kupffer cells (KCs) and hepatic stellate cells, at which point a metabolically stressed hepatocyte becomes integral to the progression of the disease.
Jeong-Su Park +22 more
doaj +7 more sources
FBG1 Is the Final Arbitrator of A1AT-Z Degradation. [PDF]
PLoS ONE, 2015 Alpha-1 antitrypsin deficiency is the leading cause of childhood liver failure and one of the most common lethal genetic diseases. The disease-causing mutant A1AT-Z fails to fold correctly and accumulates in the endoplasmic reticulum (ER) of the liver ...
John H Wen +3 more
doaj +6 more sources
Altered polyadenylation site usage in SERPINA1 3’UTR in response to cellular stress affects A1AT protein expression [PDF]
Scientific ReportsAlternative polyadenylation results in different 3’ isoforms of messenger RNA (mRNA) transcripts. Alternative polyadenylation in the 3’ untranslated region (3’UTR) can alter RNA localization, stability and translational efficiency.
F. N. U. Jiamutai +5 more
doaj +6 more sources
The Utilization of Alpha 1 Anti-trypsin (A1AT) in Infectious Disease Monitoring and Treatment.
Journal of Microbiology and Infectious Diseases, 2019 Alpha one anti-trypsin (A1AT) is a major serine protease inhibitor found circulating in human blood. A1AT related studies mainly focus on A1AT potential biomarker as well as therapeutic target in non-infectious diseases.
Irene Lorinda Indalao +5 more
doaj +5 more sources
Association of A1AT genetic polymorphism and NSCLC: a case- control study in Egyptian population [PDF]
BMC Medical Genomics, 2022 Abstract Lung cancer mortality is higher than other forms of cancer. Genetic tendency in cancer sufferers has long been known. Given the link between AATD and numerous lung disorders, it is worth investigating if this genetic trait is linked to a higher risk of developing LC, as the lung is the most afflicted organ in individuals with severe ...
Aliaa N. El-Dawa +3 more
openalex +4 more sources
Investigation of CCL18 and A1AT as potential urinary biomarkers for bladder cancer detection [PDF]
BMC Urology, 2013 Abstract Background In this study, we further investigated the association of two biomarkers, CCL18 and A1AT, with bladder cancer (BCa) and evaluated the influence of potentially confounding factors in an experimental model.
Makito Miyake +9 more
openalex +5 more sources
SUN-574 A1AT: Novel Inhibitor of Active PCSK9 [PDF]
Journal of the Endocrine Society, 2020 Abstract Heart disease is the principal cause of death and disability for both men and women in the US, accounting for 40% of all annual deaths. African American populations are disproportionately burdened with metabolic diseases, due in part to cholesterol metabolism deficiencies.
Quantil Melendez +5 more
openalex +2 more sources
P90 α-1 antitrypsin (a1AT) polymers cause extreme hepatocyte ageing [PDF]
Gut, 2011 Introduction a1AT, synthesised predominantly in the liver, is the archetypal inhibitor of the serpin protein family. a1AT deficiency is a common inherited disorder; Glu342Lys substitution causes abnormal folding of mutant protein, which may polymerise and aggregate in the endoplasmic reticulum.
Maria Mela +7 more
openalex +3 more sources
Scaled up fed-batch production of recombinant alpha-1-antitrypsin by CHO cells in single-use surface aerated orbital shaken bioreactor [PDF]
Scientific ReportsAugmentation therapy is a treatment option available in the market that has been approved by the U.S. Food and Drug Administration (FDA) for alpha-1-antitrypsin (A1AT) deficient patients.
Wen Qin Tang +6 more
doaj +2 more sources